The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Barriers to implementing CTCs in clinical practice
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the practical considerations for implementing circulating tumour cell (CTC) testing in routine myeloma care. He explains why existing flow cytometry platforms and established MRD assays may simplify adoption, and outlines how standardized methodologies could help bring CTC assessment into everyday clinical practice. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
